Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference
Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotech company specializing in Fibroblast Growth Factor Receptor (FGFR) biology, has announced its participation in the 2024 Cantor Global Healthcare Conference. CEO Todd Harris will engage in a fireside chat on September 17, 2024, at 9:45 am ET. The company's management will also conduct one-on-one meetings with investors during the event.
A live and archived webcast of the fireside chat will be accessible through the Investor section of TYRA's website. This participation underscores TYRA's commitment to engaging with the investment community and showcasing its progress in developing next-generation precision medicines targeting significant opportunities in FGFR biology.
Tyra Biosciences (Nasdaq: TYRA), un'azienda biotech in fase clinica specializzata nella biologia del recettore del fattore di crescita dei fibroblasti (FGFR), ha annunciato la sua partecipazione alla Conferenza Sanitaria Globale Cantor 2024. Il CEO Todd Harris parteciperà a una conversazione informale il 17 settembre 2024, alle 9:45 ET. Il management dell'azienda condurrà anche incontri individuali con gli investitori durante l'evento.
Un webcast dal vivo e archiviato della conversazione informale sarà accessibile attraverso la sezione Investor del sito web di TYRA. Questa partecipazione sottolinea l'impegno di TYRA nel coinvolgere la comunità degli investitori e nel mostrare i suoi progressi nello sviluppo di medicinali di precisione di nuova generazione volti a sfruttare opportunità significative nella biologia FGFR.
Tyra Biosciences (Nasdaq: TYRA), una empresa biotecnológica en etapa clínica especializada en biología del receptor del factor de crecimiento de fibroblastos (FGFR), ha anunciado su participación en la Conferencia Global de Salud Cantor 2024. El CEO Todd Harris participará en una charla informal el 17 de septiembre de 2024, a las 9:45 am ET. La dirección de la empresa también llevará a cabo reuniones uno a uno con inversores durante el evento.
Una transmisión web en vivo y archivada de la charla informal será accesible a través de la sección de Inversores del sitio web de TYRA. Esta participación subraya el compromiso de TYRA de involucrar a la comunidad inversora y mostrar su progreso en el desarrollo de medicamentos de precisión de nueva generación que apunten a oportunidades significativas en la biología del FGFR.
Tyra Biosciences (Nasdaq: TYRA)는 섬유아세포 성장 인자 수용체 (FGFR) 생물학에 특화된 임상 단계의 생명공학 회사로서 2024년 캔토 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO인 Todd Harris는 2024년 9월 17일, 동부시각 기준 오전 9시 45분에 대화형 토크에 참여할 예정입니다. 또한 회사 경영진은 행사 기간 동안 투자자들과의 일대일 미팅도 진행할 것입니다.
대화형 토크의 실시간 및 아카이브 웹캐스트는 TYRA 웹사이트의 투자자 섹션을 통해 접속할 수 있습니다. 이번 참여는 TYRA가 투자 커뮤니티와의 소통을 강조하고 FGFR 생물학에서 중요한 기회를 대상으로 하는 차세대 정밀 의약품 개발의 진전을 보여주고자 하는 의지를 나타냅니다.
Tyra Biosciences (Nasdaq: TYRA), une entreprise biopharmaceutique en phase clinique spécialisée dans la biologie des récepteurs du facteur de croissance des fibroblastes (FGFR), a annoncé sa participation à la Conférence Mondiale sur la Santé Cantor 2024. Le PDG Todd Harris participera à une discussion informelle le 17 septembre 2024, à 9h45 ET. La direction de l'entreprise tiendra également des réunions individuelles avec les investisseurs lors de l'événement.
Un webinaire en direct et archivé de la discussion informelle sera accessible via la section Investisseurs du site web de TYRA. Cette participation souligne l'engagement de TYRA à interagir avec la communauté des investisseurs et à mettre en avant ses progrès dans le développement de médicaments de précision de nouvelle génération ciblant des opportunités significatives dans la biologie FGFR.
Tyra Biosciences (Nasdaq: TYRA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das auf Biologie des Fibroblasten-Wachstumsfaktor-Rezeptors (FGFR) spezialisiert ist, hat seine Teilnahme an der 2024 Cantor Global Healthcare Conference angekündigt. CEO Todd Harris wird am 17. September 2024 um 9:45 Uhr ET an einem Gespräch teilnehmen. Das Management des Unternehmens wird während der Veranstaltung auch Einzelgespräche mit Investoren führen.
Ein live und archivierter Webcast des Gesprächs wird über den Investorenbereich der Website von TYRA zugänglich sein. Diese Teilnahme unterstreicht TYRAs Engagement, mit der Investorencommunity zu kommunizieren und Fortschritte bei der Entwicklung von next-generation Präzisionsmedikamenten aufzuzeigen, die bedeutende Chancen in der FGFR-Biologie verfolgen.
- None.
- None.
Todd Harris, CEO of TYRA, will participate in a fireside chat on Tuesday, September 17, 2024, at 9:45 am ET. TYRA management will also participate in one-on-one meetings with investors during the conference.
A live and archived webcast of the fireside chat will be available via the For Investors page on the Investor section of the TYRA website.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in
For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-the-2024-cantor-global-healthcare-conference-302245618.html
SOURCE Tyra Biosciences
FAQ
When is Tyra Biosciences presenting at the 2024 Cantor Global Healthcare Conference?
How can investors access Tyra Biosciences' presentation at the Cantor conference?
What is the focus of Tyra Biosciences' research and development?
Will Tyra Biosciences management be available for meetings during the conference?
